Press Release - Bachem

Bachem Joint Venture Pevion Biotech Secures CHF 35 Million in Series A
Financing Round
Bubendorf/Basel, Switzerland, August 9, 2007 - Bachem (SWX: BANB) today announced that
the company has participated in the first substantial private financing round of Pevion Biotech,
its joint venture founded in 2002 in partnership with Crucell N. V. The new financing round
represents a significant step in the successful development of Pevion Biotech. To date the joint
venture had exclusively been funded by its founders. Now, for the first time, also third parties
have taken part in financing Pevion Biotech, a company specialized in the development of
peptide based vaccines. Bachem contributed another CHF 2 million to this major private
Series A financing round, worth CHF 35 million in total.
Peter Grogg, founder and president of Bachem and chairman of the board of directors of
Pevion Biotech, commented: "Pevion Biotech has built an attractive vaccine portfolio with a
strong intellectual property position and is a solidly growing company in the very attractive
vaccine field. This allowed us to attract other investors experienced in healthcare for this
Series A round. The money raised renders possible a further development of the company
within the next few years."
The financing round was led by the new investor BZ Bank Aktiengesellschaft. New investors
joining the Series A also include BB Biotech Ventures II, L.P. and CC Private Equity Partners Ltd.
Pevion Biotech has raised a total of CHF 55 million to date. The new financing round will take
place in three tranches with the Bachem stake in Pevion Biotech dropping from about 50% to
eventually below 30%.
Pevion Biotech, who has three of its vaccine products in clinical testing (two projects in clinical
phase I and one project in clinical phase II), will use the funds raised in this Series A round to
advance the hepatitis C and breast cancer vaccines into clinical phase II and to progress its
pre-clinical vaccine candidates against RSV and Candida infections into clinical development.
About Bachem
Bachem is an independent, technology-based public biochemicals company providing full
service to pharma and biotech industries. Bachem is specializing in the process development
and the manufacturing of peptides and complex organic active pharmaceutical ingredients
and innovative biochemicals for research purposes. With headquarters in Bubendorf,
Switzerland and affiliates in Europe and the US, Bachem works on a global scale and holds
the leading position in the field of peptides.

About Pevion Biotech
Pevion Biotech is a privately owned Swiss biopharmaceutical company focusing on the
development of prophylactic and therapeutic vaccines based on its market-validated virosome
technology. The company is a leading specialist in the development of effective and safe
vaccines based on its proprietary technology platforms. Pevion Biotech’s development pipeline
includes, among others, vaccines against breast cancer, Candida, RSV, malaria and hepatitis
C. Pevion Biotech was founded in 2002 as a joint venture company of Bachem AG
(SWX: BANB) and Crucell N.V. (Euronext, NASDAQ: CRXL; SWX: CRX).
For further questions, please contact:
Bachem Holding AG
Michael Hüsler, CFO
Tel.+41 61 935 2333
Fax +41 61 935 2324
www.bachem.com
ir@bachem.com